Targeting α-synuclein: Therapeutic options

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 882-888

  Dehay, Benjamin ^a,b   Decressac, Mickael ^c   Bourdenx, Mathieu ^a,b   Guadagnino, Irene ^c   Fernagut, Pierre Olivier ^a,b   Tamburrino, Anna ^c   Bassil, Fares ^a,b   Meissner, Wassilios G ^a,b,d   Bezard, Erwan ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Animal models; Parkinson's disease; Propagation; Synucleinopathy; synuclein

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; GLUCOSYLCERAMIDASE; INTERLEUKIN 1BETA CONVERTING ENZYME; LEUCINE RICH REPEAT KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PRX002; MYELIN; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRION PROTEIN; TRANSCRIPTION FACTOR EB; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AUTOPHAGY; CELL INCLUSION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ENDOPLASMIC RETICULUM STRESS; EXOCYTOSIS; HUMAN; LYSOSOME; MACROAUTOPHAGY; NERVE ENDING; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; STRIATONIGRAL DEGENERATION; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; PARKINSON DISEASE;

EID: 84959541277     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26568     Document Type: Review

References (79)

1. Dehay B, Bourdenx M, Gorry P, et al. Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 2015;14(8):855-866.
2. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18(Suppl 6):S2-12.
3. Bourdenx M, Koulakiotis NS, Sanoudou D, Bezard E, Dehay B, Tsarbopoulos A. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Prog Neurobiol 2015 [Epub ahead of print].
4. Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci 2015;38:87-103.
5. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013;9(1):13-24.
6. Wakabayashi K, Hayashi S, Kakita A, et al. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 1998;96(5):445-452.
7. Uversky VN. Hot, Hotter, and Hottest Trends in alpha-Synuclein Research. Curr Protein Pept Sci 2015;16(8):682-687.
8. Dehay B, Vila M, Bezard E, Brundin P, Kordower JH. Alpha-synuclein propagation: New insights from animal models. Mov Disord 2016;31(2):161-168.
9. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 2013;28(1):31-40.
10. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009;106(31):12571-12572.
11. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013;14(1):38-48.
12. Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E. A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener 2015;10(1):48.
13. Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov Disord 2011;26(6):993-1002.
14. Magen I, Chesselet MF. Genetic mouse models of Parkinson's disease. The state of the art. Prog Brain Res 2010;184:53-87.
15. Rockenstein E, Mallory M, Hashimoto M, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 2002;68(5):568-578.
16. Westerlund M, Ran C, Borgkvist A, et al. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol Cell Neurosci 2008;39(4):586-591.
17. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002;34(4):521-533.
18. Emmer KL, Waxman EA, Covy JP, Giasson BI. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem 2011;286(40):35104-35118.
19. Ubhi K, Rockenstein E, Mante M, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 2010;30(18):6236-6246.
20. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3(6):583-588.
21. Fernagut PO, Meissner WG, Biran M, et al. Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Synapse 2014;68(3):98-106.
22. Flabeau O, Meissner WG, Ozier A, Berger P, Tison F, Fernagut PO. Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. Mov Disord 2014;29(3):388-395.
23. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002;99(16):10813-10818.
24. Bourdenx M, Dovero S, Engeln M, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun 2015;3(1):46.
25. Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 2012;45(3):939-953.
26. Van der Perren A, Toelen J, Casteels C, et al. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiol Aging 2015;36(3):1543-1558.
27. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002;22(7):2780-2791.
28. Decressac M, Mattsson B, Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp Neurol 2012;235(1):306-315.
29. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106(31):13010-13015.
30. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012;209(5):975-986.
31. Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun 2014;2(1):88.
32. Paumier KL, Luk KC, Manfredsson FP, et al. Intrastriatal injection of pre-formed mouse alpha-synuclein fibrils into rats triggers alpha-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 2015;82:185-199.
33. Peelaerts W, Bousset L, Van der Perren A, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015;522(7556):340-344.
34. Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012;33(9):2225-2228.
35. Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013;136(Pt 4):1128-1138.
36. Watts JC, Giles K, Oehler A, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A 2013;110(48):19555-19560.
37. Recasens A, Dehay B, Bove J, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014;75(3):351-362.
38. Cavaliere F, cerf L, Dehay B, et al. Lewy Body extracts from Parkinson's Disease Brains as models for high-throughput screens of neurotoxicity and α-synuclein spreading from cell-to-cell through endocytosis. In: Neuroscience Sf, editor. 45th annual meeting of Society for Neuroscience; 2015; Chicago: Society for Neuroscience.
39. Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson's disease. Mov Disord 2013;28(6):725-732.
40. Dehay B, Bove J, Rodriguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010;30(37):12535-12544.
41. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009;35(3):385-398.
42. Bourdenx M, Bezard E, Dehay B. Lysosomes and alpha-synuclein form a dangerous duet leading to neuronal cell death. Front Neuroanat 2014;8:83.
43. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351(19):1972-1977.
44. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361(17):1651-1661.
45. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38(10):1184-1191.
46. Lees AJ, Singleton AB. Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology 2007;68(19):1553-1554.
47. Dawson TM, Dawson VL. A lysosomal lair for a pathogenic protein pair. Sci Transl Med 2011;3(91):91ps28.
48. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146(1):37-52.
49. Dehay B, Ramirez A, Martinez-Vicente M, et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A 2012;109(24):9611-9616.
50. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci 2012;32(12):4240-4246.
51. Medina DL, Fraldi A, Bouche V, et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell 2011;21(3):421-430.
52. Sardiello M, Palmieri M, di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science 2009;325(5939):473-477.
53. Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science 2011;332(6036):1429-1433.
54. Settembre C, Ballabio A. Lysosome: regulator of lipid degradation pathways. Trends Cell Biol 2014;24(12):743-750.
55. Awad O, Sarkar C, Panicker LM, et al. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum Mol Genet 2015;24(20):5775-5788.
56. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci U S A 2013;110(19):E1817-1826.
57. Kilpatrick K, Zeng Y, Hancock T, Segatori L. Genetic and chemical activation of TFEB mediates clearance of aggregated alpha-synuclein. PLoS One 2015;10(3):e0120819.
58. Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci 2015;40(4):200-210.
59. Ivankovic D, Chau KY, Schapira AH, Gegg ME. Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. J Neurochem 2015 [Epub ahead of print].
60. Nezich CL, Wang C, Fogel AI, Youle RJ. MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5. J Cell Biol 2015;210(3):435-450.
61. Siddiqui A, Bhaumik D, Chinta SJ, et al. Mitochondrial Quality Control via the PGC1alpha-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin. J Neurosci 2015;35(37):12833-12844.
62. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010;29(6):596-609.
63. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 2009;284(11):6972-6981.
64. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010;145(3):182-195.
65. Baltazar GC, Guha S, Lu W, et al. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One 2012;7(12):e49635.
66. Bourdenx M, Daniel J, Genin E, et al. Nanoparticles restore lysosomal acidification defects: Implication for Parkinson's and other lysosomal-related diseases. Autophagy 2016 [Epub ahead of print].
67. Li W, West N, Colla E, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 2005;102(6):2162-2167.
68. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005;280(24):22670-22678.
69. Hoyer W, Cherny D, Subramaniam V, Jovin TM. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 2004;43(51):16233-16242.
70. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci 2010;32(3):409-422.
71. Fernagut PO, Dehay B, Maillard A, et al. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis 2014;67:133-139.
72. Wang W, Nguyen LTT, Burlak C, et al. Caspase-1 causes truncation and aggregation of the Parkinson disease-associated α-synuclein, submitted. 2015.
73. Bassil F, Fernagut PO, Bezard E, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. In: Neuroscience Sf, editor. 45th annual meeting of Society for Neuroscience; 2015; Chicago: Society for Neuroscience.
74. Freeman D, Cedillos R, Choyke S, et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013;8(4):e62143.
75. Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol 2013;125(6):795-813.
76. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012;32(39):13454-13469.
77. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011;6(4):e19338.
78. Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 2014;127(6):861-879.
79. Bezard E. Neuroprotection for Parkinson's disease: call for clinically driven experimental. Lancet Neurol 2003;2:393.